^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + Tasigna (nilotinib) (Bcr-abl inhibitor) + imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor) + S81694 (TTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)
Published date:
11/06/2019
Excerpt:
Combination of S81694 with TKI imatinib, dasatinib and nilotinib (but not ponatinib) was strongly synergistic in BCR-ABL1+ cells (Figure 1H)….Mps1i S81694 yields significant preclinical activity in T-and B-cell ALL including BCR-ABL1+ models.
DOI:
https://doi.org/10.1182/blood-2019-125641